Strategic Partnerships

• Guangzhou Institute of Biomedicine and Health (GIBH), Guangzhou, China – Malaria.

GIBH is a medical research institute affiliated with the Chinese Academy of Sciences. CWHM has been collaborating with GIBH scientists since 2010 on a project to discover and develop new medicines for malaria.

• Institute for OneWorld Health, San Francisco, CA- Childhood Diarrhea.

CWHM signed a joint research agreement in 2010 with the Institute for One World Health to discover and develop new drugs to combat diarrhea, which is the second leading cause of death worldwide in children under age 5.  Under the agreement, CWHM provides expertise in medicinal chemistry and pharmacology to identify potential anti-secretory drug candidates for future development.

• Bioventures for Global Health, San Francisco, CA- Neglected Diseases.

BVGH is the non-profit Administrator of the Partnership Hub for WIPO Re:Search, a consortium of public and private sector organizations seeking to develop solutions for neglected tropical diseases, malaria, and tuberculosis.  As an inaugural member, CWHM offers a variety of research services to partners, and has access to the consortium’s resources to advance drug development for least developed countries.

• University of Missouri-Saint Louis Medicinal Chemistry Group (MCG), Saint Louis, MO – Medicinal Chemistry.

CWHM has expanded compound design and synthesis capabilities derived from a multi-year Master Service Agreement with the nearby UMSL MCG.  The MCG is staffed with former pharmaceutical company scientists with extensive drug discovery experience, and currently collaborates with CWHM on several projects.

• H-3D Drug Discovery and Development Centre - University of Cape Town, Cape Town, South Africa- Tuberculosis and Malaria

CWHM has established a strategic collaboration with Africa’s first integrated drug discovery and development center, directed by Professor Kelly Chibale. As part of the effort to identify and evaluate therapeutic agents for tuberculosis and malaria, the groups are working to create and make available, on a non-profit basis, a new collection of clinical compounds that includes those that were discontinued in human development for other indications.

• Gateway Pharmacology Laboratories (GPL) - Saint Louis, MO - Pharmacology Services and Project Consultation

CWHM has a joint venture relationship with Gateway Pharmacology Laboratories, a preclinical pharmacology contract research organization that provides confidence in target viability, disease relevance and compound pharmacology enabling a seamless transition into clinical evaluation.

As strategic partners, GPL and CWHM work together in characterizing the effect of drug candidates in preclinical, in vivo disease, and pharmacology models. Gateway Pharmacology Laboratories operates in state-of-the-art research facilities near CWHM with a staff of highly qualified and experienced former pharmaceutical industry research professionals who have advanced multiple compounds into clinical evaluation.

Scientific Partnerships

Malaria

• Daniel E. Goldberg, M.D., Ph.D., Washington University School of Medicine, Saint Louis, MO
• Enrico Di Cera, M.D., Saint Louis University School of Medicine, Saint Louis, MO

Lymphatic Filariasis and Onchocerciasis (River Blindness)

• Eileen Devaney, Ph.D., University of Glasgow, UK
• Gabriela Chiosis, Ph.D., Sloan-Kettering Institute for Cancer Research, New York, NY

Chagas Disease

• Daniel Hoft, M.D., Ph.D., Saint Louis University School of Medicine, Saint Louis, MO

Tuberculosis

• Yie-Hwa Chang, Ph.D., Saint Louis University School of Medicine, Saint Louis, MO

Sickle Cell Disorder

• William Ferguson, M.D., Saint Louis University School of Medicine, Saint Louis, MO

Fibrotic Diseases

• Dean Sheppard, M.D., Ph.D., University of California at San Francisco, CA